DeuterOncology NV Company Profile

Background

DeuterOncology NV, established in September 2020 by Dr. Timothy Perera, is a clinical-stage biotechnology company headquartered in Liège, Belgium. The company is dedicated to developing innovative targeted therapies for cancer treatment, with a particular emphasis on enhancing the efficacy and safety profiles of existing treatments through deuteration technology. DeuterOncology's mission is to provide advanced solutions for cancer patients by addressing the limitations of current therapies, thereby improving patient outcomes and quality of life.

Key Strategic Focus

DeuterOncology's strategic focus centers on the development of deuterated small molecule inhibitors targeting the MET kinase and RAS pathways, which are critical in various cancers, including non-small cell lung cancer (NSCLC). By incorporating deuterium atoms into drug molecules, the company aims to enhance metabolic stability, reduce toxicity, and overcome resistance mechanisms associated with existing MET inhibitors. This approach positions DeuterOncology to address significant unmet needs in oncology by offering therapies with improved tolerability and sustained efficacy.

Financials and Funding

Since its inception, DeuterOncology has successfully secured funding to advance its research and development initiatives:

• February 2021: Received an early-stage venture capital investment of €1.21 million from Newton Biocapital, marking the fund's second investment in Flanders.

• January 2023: Closed a €5.65 million Series A financing round, with participation from Newton Biocapital, Noshaq, and Investsud Tech. This funding is designated for initiating the Phase I clinical study of the lead product, DO-2.

• April 2023: Awarded a €478,000 grant from the Wallonie recherche SPW to collaborate with Radiomics on developing an AI-based imaging biomarker as a companion diagnostic for DO-2.

Pipeline Development

DeuterOncology's product pipeline includes:

• DO-2: A deuterated MET kinase inhibitor currently in Phase I clinical trials (EudraCT 2022-001681-35) for patients with MET-driven cancers. Preclinical studies have demonstrated its potential to mitigate side effects associated with existing MET inhibitors and to provide sustained target inhibition.

• DO-1: A highly selective small molecule inhibitor of the MET kinase, which has shown promising preclinical results, including the ability to induce vascular normalization and reduce tumor acidification.

Technological Platform and Innovation

DeuterOncology leverages deuteration technology to enhance the pharmacokinetic and pharmacodynamic properties of its drug candidates. By substituting hydrogen atoms with deuterium, the company aims to:

• Increase Metabolic Stability: Deuterium-carbon bonds are more stable than hydrogen-carbon bonds, leading to slower metabolic degradation and prolonged drug activity.

• Reduce Toxic Metabolites: The incorporation of deuterium can decrease the formation of inactive or toxic metabolites, improving the safety profile of the drugs.

• Overcome Resistance Mechanisms: Targeting both MET and RAS pathways addresses resistance issues observed with current MET inhibitors.

This innovative approach positions DeuterOncology's therapies as potential best-in-class treatments for MET-driven cancers.

Leadership Team

• Dr. Timothy Perera: Founder and Chief Executive Officer. Dr. Perera brings extensive experience in oncology drug development and has been instrumental in guiding DeuterOncology's strategic direction and research initiatives.

• Dr. Jaap Verweij: Chief Medical Officer. Dr. Verweij contributes his expertise in clinical oncology to oversee the clinical development programs.

• Els Hubloux: Chief Financial Officer and Board Member. Ms. Hubloux provides financial leadership and strategic planning, ensuring the company's fiscal health and growth.

Leadership Changes

As of the latest available information, there have been no recent significant changes or appointments within DeuterOncology's leadership team.

Competitor Profile

Market Insights and Dynamics

The global market for MET inhibitors is experiencing growth due to the increasing prevalence of MET-driven cancers and the demand for targeted therapies. However, existing MET inhibitors face challenges related to tolerability and resistance, highlighting the need for improved treatments.

Competitor Analysis

Key competitors in the MET inhibitor space include:

• Capmatinib (Tabrecta): Developed by Novartis, approved for NSCLC patients with MET exon 14 skipping mutations.

• Tepotinib (Tepmetko): Developed by Merck KGaA, also approved for NSCLC with MET exon 14 skipping mutations.

Both drugs have demonstrated efficacy but are associated with side effects that can lead to dose reductions or discontinuation, underscoring the need for therapies with better tolerability profiles.

Strategic Collaborations and Partnerships

DeuterOncology has established significant collaborations to enhance its research and development capabilities:

• Radiomics: Partnering to develop an AI-based imaging biomarker as a companion diagnostic for DO-2, aiming to optimize patient selection and treatment outcomes.

• Newton Biocapital: As a key investor, providing financial support and strategic guidance to advance DeuterOncology's pipeline.

Operational Insights

DeuterOncology's strategic considerations include:

• Differentiation through Deuteration: Utilizing deuterium substitution to improve drug properties, setting its products apart from existing MET inhibitors.

• Focus on Unmet Needs: Targeting patient populations with limited treatment options, particularly those with MET-driven cancers.

• Collaborative Approach: Engaging in partnerships to leverage complementary expertise and technologies, enhancing the development and potential success of its therapies.

Strategic Opportunities and Future Directions

Looking ahead, DeuterOncology aims to:

• Advance Clinical Development: Progress DO-2 through clinical trials to establish its safety and efficacy, with the goal of achieving regulatory approval.

• Expand Indications: Explore the potential of its deuterated inhibitors in other MET-driven cancers beyond NSCLC.

• Enhance Diagnostic Capabilities: Develop companion diagnostics to identify patients most likely to benefit from its therapies, ensuring personalized treatment approaches.

• Seek Strategic Partnerships: Continue to build alliances that can provide additional resources, expertise, and market access to support the company's growth and mission.

Contact Information

• Website: www.deuteroncology.com

• LinkedIn: DeuterOncology LinkedIn Profile

DeuterOncology NV remains committed to transforming cancer treatment through innovative science and strategic collaborations, striving to bring new hope to patients worldwide.